Summary A novel sterically hindered platinum complex, AMD473 [cis-amminedichloro(2-methylpyridine) platinum AMD473 also showed significantly (P < 0.05) reduced cross-resistance to cisplatin in a panel of three cell lines with known acquired platinum drug resistance mechanisms (mean RF for AMD473 was 1.9, for cisplatin 9.1). Cellular accumulation of AMD473 was not reduced in two HOC cell lines (A2780cisR and 41 McisR), in which reduced cisplatin accumulation is a major mechanism of acquired cisplatin resistance. AMD473 naked-DNA binding was significantly less affected (P < 0.05) than that of cisplatin by the presence of 5 mm glutathione. Also, AMD473 almost completely circumvented acquired cisplatin resistance in a cell line (A2780cisR) with fivefold elevated intracellular glutathione levels compared with the parent A2780 cell line when measured by clonogenic assay (RF 4.5 for AMD473 vs RF 18 for cisplatin). AMD473 also showed a lower increase in IC 5 than cisplatin in an A2780 cell line model with artificially elevated glutathione levels. AMD473 DNA binding was slower than that of cisplatin on both naked and cellular DNA. AMD473 also formed DNA interstrand cross-links (ICLs) at a slower rate than cisplatin (peak ICL formation was at 5 h for cisplatin vs 2 14 h for AMD473) after equitoxic doses were exposed to HOC cells for 2 h. AMD473 ICLs in the CH1 HOC cell line were slowly formed and showed no visible signs of being repaired 24 h after removal of drug. This was paralleled by a slower, longer lasting induction of p53 protein by equitoxic doses of AMD473 in HOC cell lines with wild-type p53. This new class of sterically hindered platinum compound, selected for clinical trial in 1997, may therefore elicit improved clinical response in intrinsically and acquired cisplatin-resistant tumours in the clinic.
Anti-cancer drugs based on and including cisplatin are in widespread use for the treatment of testicular, ovarian, small-cell lung, bladder, cervical and head and neck carcinomas. While being very effective in some tumour types, such as testicular carcinomas (Loehrer et al, 1984) , cisplatin suffers from two major drawbacks, which are severe normal tissue toxicity and the frequent occurrence of initial and acquired resistance to treatment (Yarbo, 1992) . To date, the only noticeable improvement that has been made in overcoming cisplatin resistance has been by platinum complexes containing the 1,2-diaminocyclohexane (DACH) ligand (Burchenal et al, 1979) , although several clinical cases of unacceptable toxicity have led to the discontinuation of some platinum agents carrying this ligand (Canetta et al, 1990) .
Our platinum-based drug discovery programme in collaboration with the Johnson Matthey Technology Centre (and, in part, with Bristol Myers Squibb) has thus far resulted, firstly, in the successful worldwide introduction of the less toxic cisplatin analogue carboplatin (Paraplatin) (Harrap, 1985) , secondly, the ammine-dichloro-cyclohexylamine platinum(IV)], now in phase II clinical trial (Kelland et al, 1993a; McKeage et al, 1995) , and, more recently, the identification of the first trans-platinum complex possessing in vivo anti-tumour activity against a range of murine and human tumour models [JM335, trans-ammine(cyclohexylaminedichlorodihydroxo) platinum(IV)] Goddard et al, 1996) . However, while carboplatin (and JM216) have made (or may make) a substantial impact in improving quality of life for patients undergoing platinum-based chemotherapy, there remains an overwhelming need to broaden the activity of platinum-based drugs to induce responses against currently resistant tumours.
In response to the great need for new anti-cancer drugs capable of circumventing innate and acquired resistance, the novel platinum-based compound AMD473, a.k.a. JM473 (Figure 1 ), has been developed at the Institute of Cancer Research, in collaboration with the Johnson Matthey Technology Centre/AnorMED. Tumour resistance to platinum anti-cancer drugs has been shown to be due to one or more of the following mechanisms: reduced accumulation, increased cytoplasmic detoxification by cellular thiols or increased DNA repair/tolerance of platinum-DNA In vitro circumvention of cisplatin resistance 367 adducts (Kelland, 1993) . AMD473 was designed specifically to circumvent thiol-mediated drug resistance by sterically hindering its reaction with glutathione (GSH) while still retaining the ability to form cytotoxic lesions with DNA . The introduction of steric bulk at the platinum centre (using 2-methylpyridine) predicts a dissociative mechanism of substitution rather than the associative mechanism that predominates with cisplatin. This study reports on the in vitro cytotoxic properties of AMD473, mainly with regard to the circumvention of acquired cisplatin resistance in three paired cell line models with previously determined mechanisms of resistance: 4IM/4IMcisR (resistance predominantly due to reduced drug accumulation) (Loh et al, 1992; Sharp et al, 1995) , CH1/CHlcisR (resistance due to increased DNA damage repair/tolerance) (Kelland et al, 1992b; O'Neill et al, 1995) and A2780/A2780cisR (resistance due to elevated glutathione levels, reduced drug accumulation and increased DNA damage repair/tolerance) (Behrens et al, 1987; Johnson et al, 1994; Kelland et al, 1994) . AMD473 has been selected for phase I clinical trials in the UK, which are due to commence in 1997. Cell culture A panel of 11 parent human ovarian carcinomas (SKOV-3, OV1-P, A2780, HX/62, PXN94, CHI, 41M, OVCAR3, LK1, LK2 and PAl) and acquired cisplatin (cisR)-resistant sublines (A2780cisR, 4lMcisR, CHlcisR) were used in this study (Hills et al, 1989; Kelland et al, 1993a; Mellish et al, 1994) . Cells were maintained free of Mycoplasma and were grown as monolayers in Dulbecco's Modified Eagle Medium supplemented with 10% fetal calf serum (Imperial Laboratories, Andover, UK), 2 mM L-glutamine and 0.5 ,ug ml-1 hydrocortisone in a humidified 6% carbon dioxide, 94% air atmosphere.
MATERIALS AND METHODS
Growth inhibition assay Growth inhibition by platinum agents was measured using the sulphorhodamine B (SRB) assay (Skehan et al, 1990) . Between 3000 and 8000 cells, dependent upon the growth characteristics of the cell line, were seeded into the wells of 96-well plates and allowed to attach overnight. Serial dilutions of platinum drugs were then added to quadruplicate wells and the plates then left to incubate in normal growth conditions for 96 h. Plates were then fixed with 10% trichloroacetic acid and stained with SRB. Basic amino acid content in each well was measured after solubilizing the SRB stain in 10 mM Tris using a Titertek Multiscan MCC/340 MKII plate reader set at 540 nm. Mean absorbance for each drug dose was expressed as a percentage of the control untreated well absorbance and plotted vs drug concentration. IC50 concentrations are the drug concentrations that reduced the mean absorbance at 540 nm to 50% of those in the untreated control wells.
Modulation of intracellular glutathione levels
The intracellular GSH content of the A2780 ovarian carcinoma cell line was artificially elevated by exposing cells in 96-well plates to 5 mm glutathione ethyl ester for 4 h (Versantvoort et al, 1995) . Extracellular GSH ester was removed by washing with phosphate-buffered saline (PBS). Cells were then instantly exposed to platinum agents for 2 h followed by incubation in drugfree growth medium for a further 94 h. IC50 values for cisplatin and AMD473 were then determined as in the above SRB assay. Approximately 1 x 106 A2780 ovarian carcinoma cells seeded in T25 tissue culture flasks were treated with GSH ester in an identical way and measured for relative intracellular GSH content by flow cytometry using monobromobimane fluorescence as an indicator of relative GSH (Hedley and Chow, 1994 (Lowry et al, 1951) . The remainder of the sonicated cells were then analysed by flameless atomic absorption spectrophotometry (FAAS) for platinum content using Perkin Elmer models HGA700 and 1 IOOB. FAAS has been shown to have a detection limit of approximately 5 ng (1 nmol) platinum. Then, nmol platinum mg-' protein was plotted vs concentration of platinum drug exposed to the cells. This method has been previously validated and been shown to produce less than 15% variability between and within experiments (Mellish et al, 1995) .
Reactivity of platinum complexes with salmon sperm DNA
In the presence and absence of 5 mm glutathione (reduced form) 100 gM solutions of cisplatin and AMD473 were incubated at 37°C with 0.5 mg ml-l salmon sperm DNA dissolved in TE buffer (10 mm Tris, 1 mm EDTA, pH 8 (Kohn, 1987) .'4C-thymidine-labelled test cells were exposed to cisplatin and AMD473 in normal growth media, harvested, washed in icecold PBS and irradiated on ice with 5 Gy using a 2000 Ci 6OCo source. An untreated control flask containing '4C-thymidinelabelled cells was also included in the tests.3H-thymidine-labelled cells were used as an internal standard (these were irradiated on ice with 1.5 Gy using a 2000 Ci 6"Co source for 1.5 min to introduce DNA single-strand breaks). Results were plotted as the fraction of '4C-thymidine-labelled DNA retained vs the fraction of 3H-thymidine-labelled internal standard DNA retained. DNA interstrand cross-link (ICL) index was calculated using the formula: (1 -rJ 1 -r)"2 -1, as previously described (Kohn, 1987) , where r and ro are the fractions of '4C-thymidine-labelled DNA for treated vs control cells remaining on the filter when 30% of the 3H-thymidine-labelled DNA is retained on the filter. gradient gel (Sharp et al, 1995) . Proteins were then electroblotted onto a nitrocellulose filter (Millipore, Watford, UK) (Towbin et al, 1979) in transfer buffer containing 10% methanol at 300 mA for 2 h at 4°C. The nitrocellulose filter was then blocked in PBS (pH 7.6) containing 0.5% casein overnight at 4°C. p53 protein was detected using a mouse primary monoclonal antibody (DO1, Santa Cruz Biotechnology, Santa Cruz, CA, USA (Figure 2) . However, the increase in IC50 value from the most sensitive cell line to the most resistant was much lower for AMD473 (AMD473, 30.7-fold; cisplatin, 117.9-fold; carboplatin, 119.7-fold). While IC50 values determined for AMD473 and AMD494 were similar, AMD508 was approximately threefold less potent (data not shown). The pattern of response across the cell line panel was similar for all platinum drugs tested, with SKOV-3 and HX62 being most resistant whereas CH1, LK1 and LK2 were relatively sensitive. Pearson coefficient COMPARE analysis resulting from in vitro data using the National Cancer Institute 60 cell line panel indicated that AMD473 did not share a response pattern with any other agent in the databank (highest GI50 coefficient being 0.607 for chlorambucil) (personal communication, National Cancer Institute). Comparative cross-resistance profiles for AMD473, cisplatin, carboplatin, JM216 and JM335 using the 41M/41McisR, CHI/CHlcisR and A2780/A2780cisR pairs are shown in Figure 3 . The A2780cisR/A2780 comparison is of special interest for AMD473 as A2780cisR possesses significantly higher GSH levels than the respective parental line (42 ± 15 vs 7.8 ± 0.7 nmol mg-' protein respectively) (Kelland et al, 1992) . Notably, the resistance factor (RF, IC50 resistant/parent line) of 2 ± 0.3 for AMD473 for this pair of cell lines was the lowest of the lead series of platinum complexes investigated (the next lowest being 4.5 for JM216) and was significantly lower (P < 0.05) than that observed for cisplatin itself, carboplatin or JM335. The resistance factor for the unsubstituted pyridine complex AMD494 in A2780cisR/A2780 was also higher (3.5) than that observed for either AMD473 or AMD508 (RF of 2.2) (data not shown). Further, AMD473 also circumvented acquired cisplatin resistance in other cell line pairs in which elevated GSH was not involved in the resistance mechanism: 41M/4lMcisR, RF of 1.3 ± 0.15, resistance due to reduced drug transport; and CHI/CHlcisR, RF of 2.5 ± 0.7, resistance due to enhanced DNA repair and/or increased tolerance to platinum-DNA adducts. AMD473 produced similar circumvention of cisplatin resistance in the same cell line models after 2 h drug exposures in the SRB assay (Holford et al, submitted, 1997) . In addition, no cross-resistance was observed in a P-glycoprotein British Journal of Cancer (1998) Clonogenic survival AMD473 was less potent at inhibiting A2780 and A2780cisR HOC cell colony formation than cisplatin when cells were exposed to these agents for 2 h (AMD473, IC50 14 ± 0.7 gM and 63 ± 3.0 gM for A2780 and A2780cisR respectively; cisplatin, IC50 2.5 ± 0.15 gM and 45 ± 1.9 gM for A2780 and A2780cisR respectively) ( Figure 4) . As in the SRB growth inhibition assay, AMD473 showed significant circumvention of acquired cisplatin resistance in the A2780cisR cell line (RF 4.5 ± 0.06 for AMD473 vs 18 ± 1.8 for cisplatin, P < 0.05).
Drug accumulation
Cellular cisplatin accumulation was reduced (2.4-fold ± 0.23) in the A2780cisR cell line vs its parent cell line A2780 ( Figure 5A ). The cellular accumulation of AMD473 was equal in both the A2780 and the A2780cisR cell lines and at equimolar concentrations was greater than the uptake of cisplatin in the A2780 parent cell line. Significantly more AMD473 than cisplatin was accumulated in the A2780cisR cell line when equimolar concentrations of drug were exposed to the cells (P < 0.05). The 41McisR acquired resistant cell line also reduced cisplatin accumulation compared with the 41M Figure SB) . AMD473 accumulation was equal in the 41M and 4lMcisR cell lines. Significantly more AMD473 than cisplatin was accumulated in the 41McisR subline at equimolar concentrations (P < 0.05). For both cisplatin and AMD473, cellular drug accumulation increased with a linear relationship to the amount of drug exposed to the cells.
Effect of elevated cellular GSH on growth inhibition
The A2780 HOC cell line was used as a model to examine the effect of artificially elevating intracellular GSH levels as its cisplatin-resistant subline, A2780cisR, contains approximately five times higher levels of intracellular GSH. When measured by flow cytometry, GSH ester-treated A2780 cells contained significantly higher (2.1-fold, P = 0.01) intracellular GSH levels than untreated cells. AMD473 growth-inhibitory potency was less affected by elevated GSH levels than that of cisplatin. Cisplatin 2-h exposure IC50 was increased 2.2 ± 0.3-fold, whereas the 2-h IC50 of AMD473 was increased by only 1.6 ± 0.1-fold. The P-value was 0.05, bordering on statistical significance (n = 4). DNA binding for the two platinum compounds became less with time -the rate of cisplatin platination decreasing from 2 to 4 h and increasing for AMD473. This suggests that the cisplatin-DNA reaction had begun to reach equilibrium at this point and that AMD473 DNA binding shows a lag period due to its slower aquation rate in aqueous solution (aquation rate in water = 1.47 ± 0.32 x 10-5 s-' for AMD473 vs 2.98 ± 0.6 x 10-5 s-I for cisplatin) and reduced overall reactivity with hard nucleophiles, such as DNA bases . Neither cisplatin nor AMD473 DNA binding rates were affected by the presence of 500 ,UM reduced GSH (data not shown). However, in the presence of 5 mm reduced GSH, cisplatin showed approximately 50% lower platination levels on the DNA compared with the reaction without reduced GSH at 1, 2 and 4 h. AMD473 DNA binding was significantly less affected than cisplatin in the presence of 5 mm GSH at the 1-and 2-h time points (P < 0.05), but did show a 40% reduction in DNA binding rate after 4 h compared with the reaction without GSH.
Cellular DNA platination
Platination of CH1, CHlcisR, A2780 and A2780cisR HOC cell line DNA by 100 gM AMD473 and cisplatin is summarized in Figure 7 . DNA in all cell lines tested was platinated by cisplatin and AMD473 in a concentration-and time-dependent manner.
Over an 8-h time course, the DNA platination rate for 100 gM cisplatin in the CHI HOC cell line was 225 nmol Pt g-' DNA h-' Figure 9 p53 induction vs time after 2-h equitoxic (2-h IC50) exposure to cisplatin (upper panels) and AMD473 (lower panels) in A2780 and CH1 HOC cells. Note, A2780 p53 induction was only measured up to 72 h, as past this time point cell growth was restricted by confluence vs 92.5 nmol Pt g-' DNA h-1 for 100 gM AMD473. In the CHlcisR subline, DNA platination by cisplatin or AMD473 was not significantly different to that in the parent CHI cell line. In the A2780cisR subline, DNA platination by cisplatin was reduced to 40% of that in the parent cell line, which is attributed to reduced drug accumulation as well as metabolism by intracellular thiols. AMD473 DNA binding was also reduced in the A2780cisR subline, but only to 68% of that in the parent A2780 cell line. This reduction in DNA binding must be wholly attributed to intracellular metabolism, as AMD473 accumulation in the A2780 and A2780cisR cell lines have been shown to be equal.
Alkaline elution Cisplatin and AMD473 both formed DNA interstrand cross-links (ICLs) in all HOC cell lines tested (Figure 8 ). In the A2780 cell line ( Figure 8A ), cisplatin DNA ICL formation peaked at 5 h after drug exposure and was then rapidly repaired. An equitoxic concentration of AMD473 (5 x 2-h IC50 concentration) formed DNA ICLs at a slower rate than cisplatin, peaking at 14 h. In the CHI HOC cell line ( Figure 8B ), cisplatin also formed maximal levels of ICLs at 5 h, which were then rapidly repaired. 372 J Holford et al different kinetic patterns of p53 induction by cisplatin and AMD473 when exposed to equitoxic concentrations. Cisplatin p53 induction was comparatively faster than that of AMD473, but was not as long-lasting, as shown in Figure 9 . In the A2780 cell line, peak p53 induction occurred 12 h after exposure to cisplatin (2-h IC50 concentration for 2 h). An equitoxic dose of AMD473 produced peak p53 induction after 24 h in the A2780 cell line. In the CHI cell line, p53 induction by cisplatin peaked at 6 h after drug exposure and remained at high levels of expression until 48 h after drug exposure, after which the p53 protein levels decreased slowly. As with ICL formation, AMD473 p53 induction in the CHI cell line was biphasic in nature, with only weak induction of p53 protein visible for the first 24 h after drug exposure. At 48 h after drug exposure, p53 protein was more highly induced and peaked at 72 h after drug exposure.
DISCUSSION
From over 500 compounds studied in a collaborative effort between the CRC Centre for Cancer Therapeutics at the Institute of Cancer Research (Sutton, UK) and the Johnson Matthey Technology Centre, the following lead platinum complexes have emerged: carboplatin, the only cisplatin analogue to be registered worldwide (Harrap, 1985) ; JM216, now in phase II clinical trial as the first orally bioavailable platinum drug ; JM335, the first trans-platinum analogue to demonstrate attractive in vivo anti-tumour activity against a range of s.c. preclinical tumour models ; and, herein, the sterically hindered complex AMD473. In contrast to the development of carboplatin and JM216, which was predominantly on the basis of improving patient life quality during platinum-based chemotherapy, AMD473 was designed in recognition of an increasing awareness of the mechanisms by which tumours might become resistant to cisplatin/carboplatin in the clinic. Selection of AMD473 from the series of novel sterically hindered platinum compounds for clinical development was based on its superior cross-resistance profile to that of AMD494 and its superior potency over AMD508.
Reduced cisplatin accumulation (Gately and Howell, 1993 ) increased intracellular thiols, such as glutathione (Pendyala et al, 1995) and metallothionein (Kasahara et al, 1991) , and repair/tolerance of drug-DNA lesions (Calsou et al, 1993; Mamenta et al, 1994) are regular features of intrinsic and acquired cisplatin resistance. Therefore, new platinum agents capable of improving clinical response to tumours and increasing long-term patient survival must be capable of circumventing at least one of these mechanisms of resistance. As GSH has now been implicated in the regulation of drug transport in GS-X pump and multidrug resistance-associated protein (MRP)-overexpressing tumour cell lines (Ishikawa et al, 1994; Versantvoort et al, 1995) and may possibly play a role in DNA repair (Lai et al, 1989) , it appeared that reducing the reactivity of platinum agents with glutathione may be the key to improved response in resistant tumours. Recently, it has been shown that head and neck cancer patients with low glutathione Stransferase (GST) activity are 4.7 times more likely to respond to platinum-based chemotherapy than those with higher levels of GST (Nishimura et al, 1996) .
In view of the above evidence, attempts were made to introduce steric bulk at the platinum centre using heterocyclic ligands with substituents on the ring atom next to the ligand atom so as to preclude access of sulphur. Such compounds should favour a dissociative mechanism of substitution. With relatively unhindered molecules, such as cisplatin, the associative mechanism predominates and preferential reaction with sulphur donors, e.g. glutathione, occurs. In addition, the favourable anti-tumour properties previously observed with ammine/amine complexes compared with bis-ammine or bisamine complexes (Kelland et al, 1992a) were retained. The resulting complex containing a 2-methylpyridine ligand, AMD473, possesses the predicted chemical properties in being significantly less susceptible to inactivation by sulphur-containing soft nucleophiles compared with cisplatin . In addition, the resistance factor for AMD473 in an acquired cisplatin-resistant human ovarian carcinoma cell line known to possess elevated GSH levels was significantly lower than that obtained for cisplatin, carboplatin, JM335 and JM216. Also, AMD473 showed encouraging circumvention of acquired cisplatin resistance in human ovarian carcinoma cell lines in which resistance was attributable to reduced drug transport (41McisR) or enhanced DNA repair/increased tolerance of platinum-DNA adducts (CHlcisR).
The ability of AMD473 to circumvent the mechanisms of reduced cisplatin accumulation in the cisplatin-resistant cell lines could be due to reduced formation of glutathione-drug complexes and subsequent efflux through a glutathione complex-dependent transporter, e.g. GS-X pump (Ishikawa et al, 1994) or to the increased lipophilicity of AMD473 over cisplatin, which may enable it to cross the plasma membrane more freely than cisplatin, as in the case of JM216 (Sharp et al, 1995) . How AMD473 may circumvent resistance at the level of DNA damage repair/tolerance is a complex matter and could be explained by many mechanisms. However, the observation that AMD473 bifunctional cross-links may be formed and removed over a longer period of time than those produced by cisplatin may be important. Subsequent delayed and extended induction of p53 protein by AMD473 compared with equitoxic doses of cisplatin may be directly related to the time course of bifunctional adduct formation and removal. Therefore, platinum agents that form bifunctional adducts over a long time course, such as AMD473, may stimulate p53 and other downstream DNA damage-responsive elements, such as gaddl53, gadd45, p21 and c-jun (Delmastro et al, 1997) , over longer periods of time, which may alter cellular responses to the DNA damage produced by AMD473 vs cisplatin.
In summary, partial and complete circumvention of acquired platinum drug resistance combined with the mechanistic data in this report suggest that AMD473 is a promising candidate for further evaluation in vivo and in the clinic. In addition, AMD473 has been shown to possess improved activity over that of cisplatin in vivo in some human ovarian carcinoma xenograft models . AMD473 has now been approved for phase I clinical trials by the UK CRC Phase I/II committee, begining in October 1997.
